Circulating IL-6, clusterin and irisin in obese subjects with different grades of obesity: association with insulin resistance and sexual dimorphism.


Journal

Archives of endocrinology and metabolism
ISSN: 2359-4292
Titre abrégé: Arch Endocrinol Metab
Pays: Brazil
ID NLM: 101652058

Informations de publication

Date de publication:
01 Nov 2021
Historique:
pubmed: 28 4 2021
medline: 6 11 2021
entrez: 27 4 2021
Statut: ppublish

Résumé

There are discrepancies about the relationship of IL-6, clusterin and irisin with obesity and obesity associated insulin resistance and also about their sexual dimorphism. This study aimed at evaluating the circulating levels of IL-6, clusterin and irisin in obese subjects of both sexes who had different grades of obesity and examining their sexual dimorphism and their association with insulin resistance. This study included 176 non-diabetic subjects of both sexes who were classified according to their sex into two groups; the male and the female groups. The male group (88 men) was classified according to BMI into; group 1 (22 lean men), group 2 (22 class I obese men), group 3 (22 class II obese men) and group 4 (22 class III obese men). The female group (88 women) was classified according to BMI exactly as the male group. Metabolic parameters, IL-6, clusterin, and irisin levels were measured. Data were analyzed by ANOVA test, post hoc Tukey's test and independent In obese subjects of both sexes, circulating IL-6, clusterin and irisin levels were significantly elevated and positively correlated with HOMA-IR. Obese males showed significantly higher HOMA-IR, IL-6, clusterin and irisin levels than obese females. Obesity in both sexes, especially in males was associated with high levels of IL-6, clusterin and irisin and worsened the metabolic pattern. Circulating IL-6, clusterin and irisin may represent possible therapeutic targets for insulin resistance in obese subjects.

Identifiants

pubmed: 33905632
pii: 2359-3997000000336
doi: 10.20945/2359-3997000000336
pmc: PMC10065324
doi:
pii:

Substances chimiques

CLU protein, human 0
Clusterin 0
FNDC5 protein, human 0
Fibronectins 0
IL6 protein, human 0
Interleukin-6 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126-136

Références

PLoS One. 2016 Apr 29;11(4):e0154319
pubmed: 27128661
Int J Obes Relat Metab Disord. 2002 Jul;26(7):994-1008
pubmed: 12080455
J Atheroscler Thromb. 2006 Dec;13(6):314-22
pubmed: 17192696
Adv Cancer Res. 2009;104:139-70
pubmed: 19878776
Best Pract Res Clin Endocrinol Metab. 2005 Dec;19(4):547-66
pubmed: 16311216
Am J Physiol Regul Integr Comp Physiol. 2001 Jul;281(1):R66-75
pubmed: 11404280
Sao Paulo Med J. 2017 Sep-Oct;135(5):462-468
pubmed: 29116305
J Clin Endocrinol Metab. 2011 Nov;96(11):E1871-5
pubmed: 21900379
J Clin Endocrinol Metab. 1982 Feb;54(2):254-60
pubmed: 7033275
Mediators Inflamm. 2015;2015:512603
pubmed: 25918477
J Biol Chem. 2003 Nov 14;278(46):45777-84
pubmed: 12952969
J Physiol Pharmacol. 2015 Dec;66(6):811-21
pubmed: 26769830
IUBMB Life. 2016 Jul;68(7):544-56
pubmed: 27220658
J Clin Invest. 1994 Sep;94(3):1304-9
pubmed: 8083372
J Clin Endocrinol Metab. 2005 Mar;90(3):1434-9
pubmed: 15598678
East Mediterr Health J. 2009 Jul-Aug;15(4):899-905
pubmed: 20187541
Horm Metab Res. 2016 Sep;48(10):653-657
pubmed: 27632149
J Clin Endocrinol Metab. 2011 Dec;96(12):E2018-22
pubmed: 21956416
J Clin Endocrinol Metab. 2013 Dec;98(12):4899-907
pubmed: 24057291
PLoS One. 2014 Jul 30;9(7):e103351
pubmed: 25076422
Int J Mol Sci. 2017 Mar 25;18(4):
pubmed: 28346354
Cold Spring Harb Perspect Biol. 2014 Sep 04;6(10):a016295
pubmed: 25190079
Inflamm Res. 2009 Nov;58(11):727-36
pubmed: 19543691
Obes Res. 2000 Sep;8(6):411-21
pubmed: 11011907
J Diabetes Complications. 2013 Jul-Aug;27(4):365-9
pubmed: 23619195
Physiol Rev. 2008 Oct;88(4):1379-406
pubmed: 18923185
Peptides. 2013 Jan;39:125-30
pubmed: 23219488
Pediatr Res. 2011 Mar;69(3):237-42
pubmed: 21135756
Emerg Med Int. 2018 Sep 24;2018:3296535
pubmed: 30345115
Metabolism. 2013 Aug;62(8):1037-44
pubmed: 23664085
J Clin Endocrinol Metab. 2013 Apr;98(4):E769-78
pubmed: 23436919
J Physiol Pharmacol. 2018 Feb;69(1):117-125
pubmed: 29769428
Obes Sci Pract. 2016 Jun;2(2):203-209
pubmed: 27840690
Eur J Med Res. 2010 Nov 4;15 Suppl 2:120-2
pubmed: 21147638
Endocrine. 2015 Apr;48(3):878-85
pubmed: 25142747
Biomed J. 2017 Oct;40(5):257-262
pubmed: 29179880
Cytokine. 2005 Aug 21;31(4):251-7
pubmed: 16043358
Physiol Res. 2016 Jul 18;65(3):481-92
pubmed: 27070750
World J Clin Cases. 2019 Jun 26;7(12):1444-1455
pubmed: 31363472
Diabetes Care. 2019 Mar;42(3):466-475
pubmed: 30659075
Int J Biochem Cell Biol. 1995 Jul;27(7):633-45
pubmed: 7648419
Adv Immunol. 1993;54:1-78
pubmed: 8379461
J Clin Invest. 2011 Jun;121(6):2111-7
pubmed: 21633179
PLoS One. 2013 Apr 11;8(4):e60563
pubmed: 23593248

Auteurs

Rehab H Werida (RH)

Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Damanhur University, Damanhur, Egypt.

Nashwa M El-Gharbawy (NM)

Department of Internal Medicine, Diabetes & Endocrinology Unit, Faculty of Medicine, Tanta University, Tanta, Egypt.

Tarek M Mostafa (TM)

Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt, tarek.mostafa@pharm.tanta.edu.eg.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH